Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia

NCT07223190 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07223190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2028
Completion date
August 29, 2035
Enrollment
560 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

philadelphia chromosome negative b-cell precursor acute lymphoblastic leukemia